spacer
home > pmps > autumn 2019 > reliable temperature control
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Reliable Temperature Control





Most biologics require controlled temperature conditions throughout their lifecycle to maintain their efficacy and integrity. By some industry estimates, 25% of such drugs degrade or go to waste due to temperature excursions that result in $16 billion in economic losses and patient safety issues. The industry should aggressively adopt advances in packaging and information technologies such as Internet of Things (IoT) and blockchain to prevent temperature excursions in cold chains.

The Next Big Growth Markets

According to research, the biologics and biosimilar market is expected to reach $399.5 billion by 2025. More than 50% of new drug approvals in 2017 are biologics that require temperaturecontrolled environments, a trend that is anticipated to continue.

Biologics are large molecule drugs that contain a living organism or a component thereof, such as recombinant DNA and deactivated viruses. Biologic drugs are sensitive to their environmental conditions such as temperature, light exposure, humidity, shock, and vibrations and can degrade or spoil when exposed to conditions outside their stability range for a long period of time. Of all the environmental conditions, temperature stands out as the single biggest cause of drug degradation and spoilage.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author


Sujan Thanjavuru is a digital transformation thought leader in the life sciences industry. For over 20 years, Sujan has been partnering with life sciences companies to help reduce time to market of new products and drive enterprise transformation across their value chain. He is also the founder of two health IT start ups, Clinical Data and SafeRxp. Both startups have developed innovative cloudbased cognitive platforms in partnership with Carnegie Mellon University, US. Sujan continues to build innovative new IT platforms that attempt to solve structural industry problems such as counterfeit drugs, broken cold chains, high cost of drug development, and serious adverse drug reactions.


Print this page
Send to a friend
Privacy statement
News and Press Releases

WuXi STA and Dizal Pharmaceutical Sign CMC Development and Manufacturing Agreement

STA Pharmaceutical Co., Ltd., (WuXi STA) a subsidiary of WuXi AppTec and Dizal Pharmaceutical, a biotechnology company, announce a strategic partnership. Under the terms of the collaboration, WuXi STA will become the preferred CDMO partner of Dizal Pharmaceutical for GMP production, providing integrated CMC (Chemical, manufacturing and Control) process research and manufacturing services from API to drug product.
More info >>

White Papers

Driving ROI: The Case for Investing in Contract & Site Regulatory Document Management Services

DrugDev

With tight timelines and complicated regulatory documentation requirements, getting a clinical trial up and running quickly is easier said than done. Key milestones can be achieved only after the successful negotiation of clinical trial agreements and completion of essential regulatory documents. Many clinical trials are hindered by inefficient, labor-intensive processes. Prolonged, inefficient activation can hamper investigator satisfaction and, ultimately, have a negative bottom-line impact for sponsors and CROs. In addition, the Sunshine Act is heightening the importance of financial disclosure in clinical trials. Without a robust financial disclosure strategy, sponsors cannot ensure that physician self-reported financial disclosure data are aligned with the payment data being reported through the Sunshine Act, increasing financial and regulatory risk.
More info >>

 
Industry Events

INTERPHEX 2020

28-30 April 2020, Javits Center NYC


More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement